Abstract

The long-term goal is to determine how changes in the genomic pattern of 5-methylcytosine regulates expression of drug resistance genes in human tumor cells. Human multiple myeloma cell lines and drug resistant variants which have either lost the activity of a DNA repair protein, MGMT (06-methylguanine DNA methyltransferase), or overexpress the multidrug resistance gene (MDRl) will be used.
The specific aims i nclude studies (1) on clinical specimens to determine if patients that received verapamil treatment are sensitized to nitrosoureas, (2) to determine the cellular mechanisms that control MGMT and MDRl gene expression, and (3) to identify new DNA sequences that may be important in drug resistance.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA065662-05
Application #
6172450
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
1996-05-01
Project End
2001-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
5
Fiscal Year
2000
Total Cost
$106,050
Indirect Cost

  Institution

Name
University of Arizona
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721

  Publications

Vrba, Lukas; Garbe, James C; Stampfer, Martha R et al. (2015) A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics 10:1074-83
Vrba, Lukas; Garbe, James C; Stampfer, Martha R et al. (2011) Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res 21:2026-37